Profile: Sunesis Pharmaceuticals Inc (SNSS.O)

SNSS.O on Consolidated Issue listed on NASDAQ Capital Market

1.69USD
29 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$1.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,281,871
52-wk High
$8.45
52-wk Low
$1.00

Search Stocks

Sunesis Pharmaceuticals, Inc. (Sunesis), incorporated on February 10, 1998, is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company’s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.

In December 2011, the Company announced its participation in a Phase II/III randomized, controlled, multi-center trial evaluating treatment regimens against low-dose cytarabine (LD) Ara-C, in patients older than 60 years with AML or high-risk myelodysplastic syndrome (MDS). This trial, known as the Less Intensive 1, (LI-1) Trial, is being conducted by the United Kingdom's National Cancer Research Institute (NCRI). In March 2012, the first patient was enrolled in this trial. The LI-1 Trial employs a Pick a Winner randomized design to evaluate a number of investigational treatments versus LD Ara-C.

The Company’s Vosaroxin acts by deoxyribonucleic acid (DNA) intercalation and inhibition of topoisomerase II in replicating cancer cells. The resulting site-selective DNA damage rapidly causes the cancer cells to stop dividing and die. In preclinical studies, vosaroxin demonstrated anti-tumor activity and exhibited additive or synergistic activity. Clinical activity is observed in both solid and hematologic malignancies.

Company Address

Sunesis Pharmaceuticals Inc

Suite 400
395 Oyster Point Boulevard
SOUTH SAN FRANCISCO   CA   94080
P: +1650.2663500
F: +1650.2663501

Search Stocks